Telesis Bio Income After Taxes 2021-2024 | TBIO

Telesis Bio income after taxes from 2021 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.

Telesis Bio Income After Taxes 2021-2024 | TBIO

Telesis Bio income after taxes from 2021 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$142.2B
Bristol Myers Squibb (BMY)$117.1B
Gilead Sciences (GILD)$117.1B
Vertex Pharmaceuticals (VRTX)$105.1B
CSL (CSLLY)$85.9B
Regeneron Pharmaceuticals (REGN)$78.5B
GSK (GSK)$70.5B
Argenex SE (ARGX)$38B
Alnylam Pharmaceuticals (ALNY)$31.4B
BioNTech SE (BNTX)$27.4B
Biogen (BIIB)$21.7B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$17.7B
Moderna (MRNA)$15.5B
Genmab (GMAB)$13.5B
Incyte (INCY)$13.5B
BioMarin Pharmaceutical (BMRN)$12.7B
Insmed (INSM)$12.6B
Sarepta Therapeutics (SRPT)$11.6B
Bio-Techne Corp (TECH)$11.6B
Exact Sciences (EXAS)$10.8B
Vaxcyte (PCVX)$10.7B
QIAGEN (QGEN)$10.3B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$9B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8.2B